We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Show more
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE...
A California-based biotech company found a tremendous amount of success on Tuesday following the company announcing an agreement to divest its Udenyca franchise for $558.4 To read the full story...
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZIยฎ, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund...
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.ย (โCoherus,โ NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.12 | -7.74193548387 | 1.55 | 1.75 | 1.4 | 3136137 | 1.59056084 | CS |
4 | 0.275 | 23.8095238095 | 1.155 | 2.43 | 1.1401 | 10232868 | 1.63322547 | CS |
12 | 0.37 | 34.9056603774 | 1.06 | 2.43 | 0.6655 | 5351952 | 1.35207468 | CS |
26 | -0.26 | -15.3846153846 | 1.69 | 2.43 | 0.6655 | 3536397 | 1.35456918 | CS |
52 | -0.62 | -30.243902439 | 2.05 | 3.7 | 0.6655 | 3646049 | 1.9434266 | CS |
156 | -16.48 | -92.0156337242 | 17.91 | 17.94 | 0.6655 | 2490344 | 3.88831244 | CS |
260 | -16.92 | -92.2070844687 | 18.35 | 23.03 | 0.6655 | 1895256 | 6.77088013 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions